Redeye leaves its comments on Acarix following the company’s Q1 2023 report. The report contained no significant surprises, and we largely maintain our fair value range.
ANNONS
Redeye leaves its comments on Acarix following the company’s Q1 2023 report. The report contained no significant surprises, and we largely maintain our fair value range.